These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25275915)

  • 21. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients.
    Kouchak M; Malekahmadi M; Bavarsad N; Saki Malehi A; Andishmand L
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1239-1242. PubMed ID: 28956449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLT and adjunctive medical therapy: a prediction rule analysis.
    Martow E; Hutnik CM; Mao A
    J Glaucoma; 2011; 20(4):266-70. PubMed ID: 20577109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of intraocular pressure in glaucoma subjects treated with Xalatan versus generic latanoprost.
    Egan P; Harris A; Siesky B; Abrams-Tobe L; Gerber AL; Park J; Holland S; Kim NJ; Januleviciene I
    Acta Ophthalmol; 2014 Aug; 92(5):e415-6. PubMed ID: 24373426
    [No Abstract]   [Full Text] [Related]  

  • 25. [Alterations of intraocular pressure in comparison of self- and external-administered topical antiglaucomatosa during diurnal intraocular pressure measurements].
    Böhm MR; Lill TM; Eter N; Prokosch-Willing V
    Klin Monbl Augenheilkd; 2014 Aug; 231(8):810-7. PubMed ID: 25133559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Assessment of visual function under treatment with topical antiglaucoma agents and systemic vasodilators. Clinical study on glaucoma patients].
    Popa SA; Bucătariu PM; Azoicăhi D; Costin D; Manole A; Matei M; Merchez M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):455-9. PubMed ID: 21870740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal effect of topical antiglaucoma medications on central corneal thickness.
    Viswanathan D; Goldberg I; Graham SL
    Clin Exp Ophthalmol; 2013; 41(4):348-54. PubMed ID: 22958109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An objective evaluation of eyedrop instillation in patients with glaucoma.
    Stone JL; Robin AL; Novack GD; Covert DW; Cagle GD
    Arch Ophthalmol; 2009 Jun; 127(6):732-6. PubMed ID: 19506189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
    Hermann MM; Papaconstantinou D; Muether PS; Georgopoulos G; Diestelhorst M
    Acta Ophthalmol; 2011 Jun; 89(4):e300-5. PubMed ID: 21106046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients.
    Sorkhabi R; Alipanahi R; Eftakhari-Milani A; Ghojazadeh L
    J Glaucoma; 2011; 20(4):240-3. PubMed ID: 20577116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring.
    Hermann MM; Bron AM; Creuzot-Garcher CP; Diestelhorst M
    J Glaucoma; 2011 Oct; 20(8):502-8. PubMed ID: 20852438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating eye drop instillation technique in glaucoma patients.
    Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
    J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Shimmyo M
    Am J Ophthalmol; 2005 Jun; 139(6):1148; author reply 1148-9. PubMed ID: 15953471
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of intraocular pressure-lowering effect of every night versus every other night dosing of bimatoprost 0.03%.
    Shazly TA; Latina MA
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):369-71. PubMed ID: 21663517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ketorolac add-on treatment on intra-ocular pressure in glaucoma patients receiving prostaglandin analogues.
    Turan-Vural E; Torun-Acar B; Acar S
    Ophthalmologica; 2012; 227(4):205-9. PubMed ID: 22116588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Peak pulse blood volume and topical antiglaucoma drugs in rhesus monkeys with experimental open angle glaucoma].
    Schmidt KG; von Rückmann A; Eisenmann D; Stegman DY; Mittag TW
    Klin Monbl Augenheilkd; 1998 Dec; 213(6):341-6. PubMed ID: 10048011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.